Navigation Links
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Date:10/18/2011

RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 20389876.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 25, 2011 to midnight ET on November 1, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 20389876.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of ZFP Therapeutics®, novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
2. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
3. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
5. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sangamo Announces Public Offering of Common Stock
9. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
10. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... In her thought ... transports the reader to a not-so-distant future faced with an Ebola pandemic that is ... who overcomes personal tragedy to enter the world of counterterrorism, and who continues to ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, CSOs, CMOs, ... management space join prominent academics and key investors for Neuro Advance Boston, October ... in Boston. , Neuro Advance Boston focuses on the latest developments and ...
(Date:9/1/2015)... , Sept. 1, 2015   Medfusion, Inc., ... the relationship between doctors and patients, today announced ... Durham, N.C. -based venture capital firms.   ... business association with Bull City Venture Partners and ... Medfusion Founder and Executive Chairman. "Both firms, experience ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... their 2008 Annual,Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX ) ... Douglas T. Brown, Senior VP and Manager of Corporate Banking Government ... Cox, Jr., Principal, Asset Protection Company -- Claire L. Kruger, ... Spherix -- Gilbert V. Levin, Ph.D., Director of Science and ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Spherix Holds Annual Shareholders Meeting 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... biosensor microchip that could significantly speed up the ... highly sensitive "nanosensors," analyze how proteins bind to ... effectiveness and possible side effects of a potential ... nanosensors can simultaneously and continuously monitor thousands of ...
... oil spill caused social disruption and psychological stress among ... the Exxon Valdez spill and the impacts are likely ... "Just ask the residents of Cordova today whether they ... Ritchie, assistant director for research of the University of ...
... study by researchers at the Virginia Institute of Marine ... does kill large numbers of copepodstiny crustaceans that are ... studyby VIMS graduate student Samantha Bickel, VIMS professor Kam ... the March issue of the Journal of Experimental ...
Cached Biology News:New biosensor microchip could speed up drug development, Stanford researchers say 2New biosensor microchip could speed up drug development, Stanford researchers say 3Gulf oil spill similar to Exxon Valdez in initial social and mental impacts, study finds 2VIMS study: Propeller turbulence may affect marine food webs 2VIMS study: Propeller turbulence may affect marine food webs 3
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Low Speed Shaker ,Product Information ... shaker is a high quality, general purpose shaker ... after the other models in the line, the ... easy-access control panel. Electronic controls are utilized for ...
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
... ActiveSight, the leading provider of X-ray ... offers fragment-based screening services to its ... involves the binding of drug-like fragments ... protein drug targets, allowing scientists to ...
Biology Products: